about
Alcohol and HIV Effects on the Immune SystemIncident fractures in HIV-infected individuals: a systematic review and meta-analysisKey toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen.Bones, Fractures, Antiretroviral Therapy and HIV.Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adultsIncreased Fracture Incidence in Middle-Aged HIV-Infected and HIV-Uninfected Women: Updated Results From the Women's Interagency HIV StudyBone Density and Fractures in HIV-infected Postmenopausal Women: A Systematic Review.Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial.Viability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations.Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis.The protease inhibitors and HIV-associated bone loss.Bone health in children and adolescents with perinatal HIV infectionDoes systemic inflammation and immune activation contribute to fracture risk in HIV?Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiationBone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy.Comparative risk of fracture in men and women with HIV.Metabolic consequences of HIV: pathogenic insights.Adverse skeletal effects of drugs - beyond Glucocorticoids.Bone Disease in HIV: Recommendations for Screening and Management in the Older Patient.Hepatitis C virus coinfection as a risk factor for osteoporosis and fracture.Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort.Comparison of two different strategies of treatment with zoledronate in HIV-infected patients with low bone mineral density: single dose versus two doses in 2 years.Bone quality assessed using quantitative ultrasound at the distal radius does not differ in antiretroviral therapy-naïve HIV-positive and HIV-negative Rwandan women.An increased rate of fracture occurs a decade earlier in HIV+ compared with HIV- men.Antiretroviral Therapy Containing HIV Protease Inhibitors Enhances Fracture Risk by Impairing Osteoblast Differentiation and Bone Quality.Bone mineral density changes after 2 years of ARV treatment, compared to naive HIV-1-infected patients not on HAART.Fractures Are Not Associated with CD8(+) T Cell Activation: An Analysis of the ACTG ALLRT Study.Comorbidities Among US Patients With Prevalent HIV Infection-A Trend Analysis.HIV and the menopause: A review.The Differential Effects of HIV and HCV on Bone Micro-Architecture and Fracture risk.Tenofovir-Associated Bone Adverse Outcomes among a US National Historical Cohort of HIV-Infected Veterans: Risk Modification by Concomitant Antiretrovirals.Continued Interest and Controversy: Vitamin D in HIV.HIV and Vertebral Fractures: a Systematic Review and Metanalysis.The Hidden Burden of Fractures in People Living With HIVThe impact of common co-morbidities (as measured using the Charlson index) on hip fracture risk in elderly men: a population-based cohort study
P2860
Q26773216-8FA45738-9A8B-4421-9E8B-64B7E7E05693Q33648297-260E3DAD-4267-4837-89B6-2A4356C5A066Q34536677-22F9B953-02CE-46E5-B1AC-90AC9125973BQ34556859-49D787FF-2891-44DF-BC38-A164489C9DE9Q35743556-F4729E7F-2C82-4CD5-A822-8701157F5F54Q36019580-5D52EE3B-F45C-40D8-8C24-63162CF7BAC5Q36069498-A747336B-A2C8-4C4F-B3C6-2AE2E213D643Q36170370-DA70D1CA-B14C-452D-8FCE-ED44078C9667Q36275141-277C99AB-333A-4588-8F9F-D810BCF5373DQ36399193-CF8CBD13-6591-4155-92BA-0D8BD4D8B8A5Q36818259-A19F996F-A3AC-4D64-A45B-3F3E9F646002Q36941678-B51B5850-A891-4A81-8D34-ED6A71D17784Q37138907-E847A9C3-CB9E-4492-9F9C-AA1D9D73A43DQ37247235-85B156EF-E01D-4757-A07C-0185FC4B8FC9Q37272765-2E191FA2-1A87-4D5B-ACEF-8F7727E5CA51Q37554792-CCC6E800-3D58-4288-947E-787FD809F22DQ38175873-5B795F9F-AB18-46AE-A67F-180B328CC9F2Q38231316-04D41A7A-C316-4650-B2F0-264E6829A47EQ38540406-475A7AD7-5CB6-449F-8320-1CB4053C56B4Q38738823-4759443C-EFE2-4CCB-AE1D-22BAD8EB66FBQ38915191-DD32D85B-1CA8-43B1-9DCC-758FDDB15003Q39010553-06E52CBF-F1B0-46B9-A8B6-FA4ED16D9328Q39781091-3CADF961-E474-4480-96A3-033508FCE6BFQ40187684-9AA74A04-90E4-4BAF-9524-FCCD8F31BBBBQ40194342-EE248553-8E85-4072-90D4-24831584AAE6Q41647237-4B22FDE5-738E-4B0E-98B5-F111290F68B5Q42434463-810A04BC-AC04-44B0-99A5-DB36F58BC7B9Q47290271-5380A4E6-E6C7-43E4-9CC1-7EB5C6EFBE4FQ47292815-00082272-CE07-4C09-84B7-9067C49C5271Q49960105-ECCB96B0-EFEB-4D7A-9FC2-A63B5A4F0455Q52729705-D7B4D54A-986A-4994-A47D-CCC8B67ED079Q54224147-8B2B01C5-340D-45FE-A9D0-A4700474A4E3Q55398207-31FB334B-9126-4CAE-9223-17E7313FD5D0Q57143538-6420147F-CAF7-42CF-955C-F1E8F65981C6Q57416932-23F7EFE3-3FCB-401B-BD17-EF7402842221
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Fractures after antiretroviral initiation.
@en
type
label
Fractures after antiretroviral initiation.
@en
prefLabel
Fractures after antiretroviral initiation.
@en
P2093
P2860
P1433
P1476
Fractures after antiretroviral initiation.
@en
P2093
Grace A McComsey
Hector Bolivar
Jeannie S Huang
Katherine Tassiopoulos
Marc Hochberg
Marshall J Glesby
Michael T Yin
Michelle A Kendall
P2860
P304
P356
10.1097/QAD.0B013E328359A8CA
P407
P577
2012-11-01T00:00:00Z